secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-082520
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon files $400M ATM equity prospectus supplement; $291M already sold under prior program
--------------------------------------------------------------------------------

- Filed prospectus supplement to register up to $400M of common shares for at-the-market (ATM) sales.
- Prior ATM sales total $291,084,564 as of filing date; prior program terminated.
- Sales agents are Jefferies and Stifel; shares issuable under Sales Agreement dated Aug 2020 as amended.
- Registration statement automatically effective on Form S-3 filed Aug 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526082520/0001193125-26-082520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000119312526082520/xene-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-082520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer